Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 4/20 | 0.41 |
| ▸ | MMP2 | P08253 | 4/20 | 0.41 |
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | MMP16 | P51512 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3097794 | 0.91 | BCL2L1 (0.41) | BCL2L1MCL1MMP9MMP2MMP13 | |
| SCHEMBL3083883 | 0.90 | EGFR (0.48) | MMP9MMP2MMP13MMP8 | |
| SCHEMBL3087959 | 0.88 | EGFR (0.45) | LMNA | |
| SCHEMBL3092907 | 0.87 | USP30 (0.41) | — | |
| SCHEMBL3092840 | 0.87 | EGFR (0.44) | MMP2MMP13MMP1MMP3LMNA | |
| SCHEMBL3092864 | 0.86 | LARS1 (0.48) | LMNANPY5R | |
| SCHEMBL3089589 | 0.85 | USP30 (0.42) | — | |
| SCHEMBL3096770 | 0.85 | EGFR (0.39) | LMNA | |
| SCHEMBL3091920 | 0.83 | CCR5 (0.39) | BCL2L1MCL1 | |
| SCHEMBL3097806 | 0.82 | FBP1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | TARS1 736/4885BCL2L1 3351/4885MCL1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.